January 26, 2015
The FDA granted orphan drug designation to liposomal encapsulated paclitaxel, or LEP-ETU, an ovarian cancer treatment in development by Insys Therapeutics Inc., the company announced today.
“We are pleased to have received orphan drug designation for LEP-ETU to treat ovarian cancer, a devastating and difficult-to-treat disease,” Michael L. Babich, president and CEO of Insys Therapeutics, said in a press release. “By entrapping the paclitaxel with liposomes, we believe our LEP-ETU formulation could potentially have reduced toxicity, while maintaining or enhancing efficacy of the cancer-fighting paclitaxel. We are currently evaluating next steps with respect to this drug product candidate.”